Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival

Wang, Ruo Xi; Chen, Sheng; Huang, Liang; Zhou, Ying; Shao, Zhi Ming

doi:10.1634/theoncologist.2017-0602

Cited by 24 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGFs are also involved in tumour cell migration as regulators of BC proliferation and tumour cell escape from apoptotic signals. This characteristic makes VEGFs a potential target candidate in BC patients in the neoadjuvant setting [93]. Arai et al [94] suggested that VEGFs also play an essential role in trastuzumab therapy by minimising the allocation of tumour cells to the lymphatic vessels in HER2-positive BC.…”

Section: Tumour Cell Intravasationmentioning

confidence: 99%

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype

et al. 2020

View full text Add to dashboard Cite

Lymphovascular invasion (LVI) is associated with poor outcome in breast cancer (BC); however, its underlying mechanisms remain ill-defined. LVI in BC develops through complex molecular pathways involving not only the interplay with the surrounding microenvironment along with endothelial cells lining the lymphovascular spaces but also changes in the malignant epithelial cells with the acquisition of more invasive and migration abilities. In this review, we focus on the key features that enable tumour cell detachment from the primary niche, their migration and interaction with the surrounding microenvironment as well as the crosstalk with the vascular endothelial cells, which eventually lead to intravasation of tumour cells and LVI. Intravascular tumour cell survival and migration, their distant site extravasation, stromal invasion and growth are part of the metastatic cascade. Cancer cell migration commences with loss of tumour cells' cohesion initiating the invasion and migration processes which are usually accompanied by the accumulation of specific cellular and molecular changes that enable tumour cells to overcome the blockades of the extracellular matrix, spread into surrounding tissues and interact with stromal cells and immune cells. Thereafter, tumour cells migrate further via interacting with lymphovascular endothelial cells to penetrate the vessel wall leading ultimately to intravasation of cancer cells. Exploring the potential factors influencing cell migration in LVI can help in understanding the underlying mechanisms of LVI to identify targeted therapy in BC.

show abstract

Section: Tumour Cell Intravasationmentioning

confidence: 99%

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A correlation between VEGF and shorter relapse-free and overall survival in breast cancer patients have been reported previously [27]. In TNBC, Wang et al reported that monitoring serum VEGF can be an early predictor of response to treatment and patients' survival [28].…”

Section: Discussionmentioning

confidence: 64%

VEGF and KRAS are Potential Targets of miR-206 Modulation in Triple Negative Breast Cancer

Feky¹,

Ibrahim²,

Nassar³

et al. 2019

JCRT

View full text Add to dashboard Cite

Triple negative is a subtype of breast cancer characterized by lack of expression of hormone receptors (ER, PR and Her2/neu). Due to the limited treatment options, the search for novel treatment targets continues. The aim of this study was to assess the differential expression of miR-206, VEGF and KRAS in TNBC and non-TNBC tissues and cell lines and to evaluate the modulatory effect of miR-206 on the key oncogenic targets VEGF and KRAS. The expression of miR-206, VEGF and KRAS was quantified using real time PCR in both paraffin embedded breast cancer and adjacent tissues as well as in MDA-MB-231 and MCF-7 cell lines. Cell lines were transfected with different concentrations of miR-206 mimic and their viability were assessed using MTT assay. Our results indicated that miR-206 was significantly downregulated in cancerous compared to non-cancerous tissues with a more pronounced downregulation in TNBC than non-TNBC tissues. VEGF and KRAS were significantly upregulated in TNBC compared to non-TNBC and their expression was negatively correlated to miR-206 expression. Transfection of TNBC and non-TNBC cell lines with miR-206 mimic resulted in a dose dependent reduction in cell viability as well as a significant reduction in VEGF and KRAS expression. In conclusion, based on our combined human tissues and cell line-based investigations we can suggest that VEGF and KRAS may be potential targets for miR-206-mediated regulation and that their targeting by miR-206 can be a highly efficient therapeutic strategy in TNBC.

show abstract

“…49 Serum MMP-9, VEGF and secreted protein acidic and rich in cysteine (SPARC) were promising biomarkers to predict responses to NAC and prognosis of TNBC patients. 51,52 miRNA Alternation…”

Section: Small Molecular Changes With the Use Of Nac Changes In Subtypesmentioning

confidence: 99%

<p>Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review</p>

Xu¹,

Chen²,

Deng³

et al. 2020

OTT

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NAC) largely increases operative chances and improves prognosis of the local advanced breast cancer patients. However, no specific means have been invented to predict the therapy responses of patients receiving NAC. Therefore, we focus on the alterations of tumor tissue-related microenvironments such as stromal tumor-infiltrating lymphocytes status, cyclin-dependent kinase expression, noncoding RNA transcription or other small molecular changes, in order to detect potentially predicted biomarkers which reflect the therapeutic efficacy of NAC in different subtypes of breast cancer. Further, possible mechanisms are also discussed to discover feasible treatment targets. Thus, these findings will be helpful to promote the prognosis of breast cancer patients who received NAC and summarized in this review.

show abstract

Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival

Cited by 24 publications

References 30 publications

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype

VEGF and KRAS are Potential Targets of miR-206 Modulation in Triple Negative Breast Cancer

<p>Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review</p>

Contact Info

Product

Resources

About